Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Dato-DXd + Rilvegostomig for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Trois-Rivieres, Quebec
This trial aims to see how well a new drug called Dato-DXd works when used alone or with another drug, compared to the standard treatment pembrolizumab, for patients with a specific
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service